December 5 – 6, 2022 | Washington DC, USA

Contact Us
Metabolic, Hepatology, Nephrology and Cardiovascular Cross Talk
Cardiologist, endocrinologist and hepatologist trialists, industry, regulatory experts, payers, patients representatives and other stakeholders crosstalk summit.
A Multi-stakeholder Multi-specialty NASH Trialists Think Tank

A Multi-stakeholder Multi-specialty NASH Trialists Think Tank

Metabolic, Hepatology, Nephrology and Cardiovascular Cross Talk

Organized by the Translational Medicine Academy

TMA logo

In collaboration with CardioVascular Clinical Trialists Forum 

and Liver forum

Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Overview
MOSAIC - the 1st Global NASH Trialist Forum
will bring together cardiology, endocrinology & hepatology clinicial trialists, industry, regulatory experts, payers, patients representatives and other stakeholders to further advance collective intelligence and foster collaboration about NASH diagnosis and management.
NASH: a major unmet need in clinical trial science
it is now clear that non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are a public health problem worldwide.
• It affects around 25-30% of the adult population and causes considerable liver-related and extra-hepatic morbidity and mortality.
• NASH is considered a metabolic and multi organ disease with cardiovascular complications, worsening metabolic dysfunction and other extra-hepatic diseases, such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), or certain extra-hepatic cancers.
MOSAIC - the 1st Global Nash Trialist Forum
will bring together cardiology, endocrinology & hepatology clinicial trialists, industry, regulatory experts, payers, patients representatives and other stakeholders to further advance collective intelligence and foster collaboration about NASH diagnosis and management.
NASH: a major unmet need in clinical trial science
it is now clear that non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are a public health problem worldwide.
• It affects around 25-30% of the adult population and causes considerable liver-related and extra-hepatic morbidity and mortality.
• NASH is considered a metabolic and multi organ disease with cardiovascular complications, worsening metabolic dysfunction and other extra-hepatic diseases, such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), or certain extra-hepatic cancers.
Countdown to conference
[hurrytimer id="890"]
Learning Objectives
Why you should attend?
  • list icon
    Networking opportunities
  • list icon
    Think Tank focused Workshops
  • list icon
    Latest trials updates
  • list icon
    Patient participation
Chairs
Stephen Harrison
USA
Veronica Miller
USA
Arun-Sanyal-USA
Arun Sanyal
USA
Ellipse chair
Faiez Zannad
France
Thursday 30 June 2022
Topics
  • NASH – Cardiovascular Intersections
  • Epidemiology, disease mechanisms
  • NonInvasive Tests (NITs)
  • Trial design issues and innovations
  • Patient population selection in NASH trials
  • Endpoints
  • Pathways to approval
  • Therapeutics
  • Experiences and case studies
Presentations and Discussion
  • How do SGLT2 inhibitors bring about cardiorenal benefits?
    Subodh Verma, Toronto, ON, Canada
  • Totality of evidence in heart failure
    Deepak L. Bhatt, Boston, MA, USA
  • Trial results coming out soon
    Stefan D. Anker, Berlin, Germany
  • Heart failure guidelines – July 2021 update
    Marco Metra, Brescia, Italy
  • Panel Discussion
Meet The Expert Breakout Sessions
  • Early treatment initiation in the hospital setting
    Mark C. Petrie, Glasgow, UK
    Deepak L. Bhatt, Boston, MA, USA
  • Managing patients with comorbidities (T2D & CKD)
    Paola Fioretto, Padova, Italy
    Katherine R. Tuttle, Spokane, WA, USA
  • Interdisciplinary collaboration and care transitions
    Subodh Verma, Toronto, ON, Canada
    Faiez Zannad, Nancy, France
Industry-Sponsored Satellite Symposia
  • Details coming soon
Programs
  • Session 7: Use of NITS for efficacy and safety assessment- circulating biomarkers
  • Session 8: Use of NITs for efficacy and safety assessment- Imaging
  • Session 9: Therapeutics
  • Session 10: Breakout sessions and report back
What is Lorem Ipsum 2 ?
  • Lorem Ipsum is simply dummy text of the printing and typesetting industry.t
    Lorem ipsum dolor sit amet
    Lorem ipsum dolor sit amet
  • Lorem Ipsum is simply dummy text of the printing and typesetting industry.
    Lorem ipsum dolor sit amet
    Lorem ipsum dolor sit amet
  • Lorem Ipsum is simply dummy text of the printing and typesetting industry.
    Lorem ipsum dolor sit amet
    Lorem ipsum dolor sit amet
Sponsors